Evidence map›Paper›PMID 31467752›Full record

ArticleCase reports in ophthalmological medicine2019

Bilateral Retinal Angiomatous Proliferation in a Variant of Retinitis Pigmentosa.

G Aloe, C M De Sanctis, C Strafella, R Cascella, F Missiroli, M Cesareo, E Giardina, F Ricci

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in ophthalmological medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

G AloeUnit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy.ORCID https://orcid.org/0000-0002-7624-1041
C M De SanctisUnit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy.
C StrafellaDepartment of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.ORCID https://orcid.org/0000-0003-1334-0920
R CascellaMolecular Genetics Laboratory UILDM, Santa Lucia Foundation, Rome, Italy.ORCID https://orcid.org/0000-0002-2148-0758
F MissiroliUnit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy.
M CesareoUnit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy.
E GiardinaDepartment of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
F RicciUnit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy.
Policlinico Tor Vergata · ITUniversity of Rome Tor Vergata · ITCatholic University Our Lady of Good Counsel · AL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the first case of bilateral retinal angiomatous proliferation (RAP) in a patient with a variant of retinitis pigmentosa (RP). CASE REPORT: An 85-year-old man with RP presented with visual acuity decrease and metamorphopsia in the left eye (LE). Fundus examination revealed typical signs of RP in both eyes, associated with intraretinal macular hemorrhage in the LE. Multimodal imaging, using Colour fundus Photography, Fluorescein (FA), and Indocyanine Green Angiography (ICGA) as well as Spectral-Domain Optical Coherence Tomography (SD-OCT) and Optical Coherence Tomography Angiography (OCTA), revealed a type 3 neovascular lesion in the involved eye. Genetic testing (NGS analysis) was performed to search for genetic variants correlated with the disease phenotype displayed by the patient. The patient was treated with intravitreal injections of bevacizumab, according to a fixed protocol of bimonthly injections plus a booster dose at second month. After 9 months, he was referred for visual acuity decrease and metamorphopsia in the fellow eye, where SD-OCT/OCTA showed a type 3 neovascular lesion in the right eye (RE). He was scheduled for intravitreal injections of bevacizumab. In both eyes, treatment with intravitreal bevacizumab was successful.

Identifiers

PMID31467752
PMCPMC6699319
OpenAlexW2964675357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.